ADJUVANT CAPITAL
Adjuvant Capital is a life sciences investment firm focused on global health. The company makes $10-$25 million investments in ambitious companies targeting opportunities in high burden and neglected disease. Adjuvant Capital was founded in 2012 by Charlie Petty, Glenn Rockman, and Kabeer Aziz and is based in New York.
ADJUVANT CAPITAL
Industry:
Financial Services Health Care Venture Capital
Founded:
2012-01-01
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins Euro Microsoft Exchange Online
Current Advisors List
Advisor
2019-09-01
Current Employees Featured
Charlie Petty Principal @ Adjuvant Capital
Principal
2017-02-01
Michael Chang Principal @ Adjuvant Capital
Principal
2018-10-01
Kabeer Aziz Principal @ Adjuvant Capital
Principal
Jenny Yip Managing Partner @ Adjuvant Capital
Managing Partner
2019-02-01
Philippe Dro Partner @ Adjuvant Capital
Partner
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-02-16 | Memo Therapeutics | Adjuvant Capital investment in Series B - Memo Therapeutics | 23 M CHF |
| 2022-01-07 | Curevo | Adjuvant Capital investment in Series A - Curevo | 60 M USD |
| 2021-11-02 | Antiva Biosciences | Adjuvant Capital investment in Series D - Antiva Biosciences | 31 M USD |
| 2021-09-16 | 54gene | Adjuvant Capital investment in Series B - 54gene | 25 M USD |
| 2021-07-07 | VitriVax | Adjuvant Capital investment in Series A - VitriVax | N/A |
| 2021-05-27 | Pulmocide | Adjuvant Capital investment in Series C - Pulmocide | 92 M USD |
| 2021-02-24 | Yisheng Biopharma | Adjuvant Capital investment in Series B - Yisheng Biopharma | 130 M USD |
| 2021-02-17 | Excision BioTherapeutics | Adjuvant Capital investment in Venture Round - Excision BioTherapeutics | 60 M USD |
| 2021-02-03 | Frontier Nutrition | Adjuvant Capital investment in Series B - Frontier Nutrition | 6 M USD |
| 2021-02-02 | Excision BioTherapeutics | Adjuvant Capital investment in Series A - Excision BioTherapeutics | N/A |
More informations about "Adjuvant Capital"
About - Adjuvant Capital
Adjuvant Capital’s assets under management covered by the Impact Principles totals $300 million USD, for the period ending September 30, 2023. Our detailed BlueMark verification report can be found here. Assets under management …See details»
Team - Adjuvant Capital
Adjuvant is a life sciences investment fund that backs ambitious companies developing drugs, vaccines, diagnostics, medical devices, and other technologies to address critical global public …See details»
Adjuvant Capital - Investments, Portfolio & Company Exits
Adjuvant Capital 's most notable exits include AN2 Therapeutics, Evofem Biosciences, and Themis Bioscience. Which industries has this organization had the most exits in? Show . AN2 …See details»
Shingles vaccine maker Curevo lands $110M, adds biotech vets to …
5 days ago The fresh cash will help Curevo advance Phase 2 trials of amezosvatein, its shingles vaccine built from a non-living component of the virus and a proprietary adjuvant, a substance …See details»
Adjuvant Capital: Investment in Health Innovations
Apr 16, 2021 Adjuvant Capital’s investment fund could possibly produce life-changing healthcare solutions that have the potential to create significant global social impact. Adjuvant Capital is …See details»
Adjuvant Capital - Using Venture Capital to Improve Global Health …
Adjuvant is a new type of venture capital firm. We finance the most promising life science technologies for high-burden public health challenges. We see enormous opportunities in …See details»
Adjuvant Capital - Devex
The Adjuvant model pursues meaningful, measurable social impact on top of its financial return objectives. History. Their roots date back to efforts by the Bill & Melinda Gates Foundation and …See details»
Adjuvant Capital Raises $300 Million Global-Health …
Feb 18, 2021 Adjuvant Capital, led by Glenn Rockman and Jenny Yip, held the final closing of its first fund in December and expects to make 20 to 25 investments from the pool. Photo: Benjamin Norman Media.See details»
Adjuvant Capital - teaserclub.com
Adjuvant Capital is a life sciences investment firm focused on global health. We make $10-$25 million investments in ambitious companies targeting opportunities in high burden and …See details»
Adjuvant Capital - Recent News & Activity - Crunchbase
6 days ago Adjuvant Capital raised a new fund: Adjuvant Capital Fund ($300,000,000) Funding Round • Feb 17, 2021 Excision BioTherapeutics raised $60,000,000 / Series Unknown from …See details»
Adjuvant Capital - Contacts, Employees, Board Members
Adjuvant Capital has 6 current employee profiles, including Principal and Co-Founder Charlie Petty. Adjuvant Capital has 2 board members and advisors, including Alexandra Glucksmann. …See details»
Adjuvant Capital announces $300m venture fund to improve …
Glenn Rockman, Managing Partner, Adjuvant Capital: "Billions of people around the world live under constant assault from diseases like malaria, shigella, hookworm, tuberculosis, and …See details»
Portfolio - Adjuvant Capital
Adjuvant is a life sciences investment fund that backs ambitious companies developing drugs, vaccines, diagnostics, medical devices, and other technologies to address critical global public …See details»
CDC invests in Adjuvant Capital's $300 million venture fund …
Feb 18, 2021 CDC Group has today announced its invested in a $300 million fund from Adjuvant Capital focused on accelerating the development of medical innovations for historically …See details»
Adjuvant Capital
Adjuvant Capital is a venture Capital firm focused on improving global health by financing life science technologies for highburden public health challenges. They see opportunity in …See details»
Adjuvant Capital Company Profile | Management and Employees …
Adjuvant Capital Profile and History. Adjuvant Capital is a life sciences investment firm focused on global health. We make $10-$25 million investments in ambitious companies targeting …See details»
Gates, Merck and Novartis-backed Adjuvant Capital raises $300M …
Feb 18, 2021 A major group of pharma and charitable groups have joined forces to raise a $300 million venture round for Adjuvant Capital as it goes after forgotten diseases across the globe.See details»
Adjuvant rakes in $300m for debut public health fund
Feb 18, 2021 Adjuvant Capital has raised $300 million for its new venture fund focused on improving global public health. The fund’s investors include Merck, Novartis, IFC, Bill & …See details»
Adjuvant/Capital Profile
Adjuvant/Capital (UEI NW46TZTMF8B5, CAGE 7DHG1) based in San Antonio TX federal contracts, grants, registrations, vehicles, partnerships, and analysisSee details»
Curevo Raises $110 Million to Advance Amezosvatein Shingles …
6 days ago About Adjuvant Capital Headquartered in New York, with offices in Zürich, Adjuvant is a global life science investment fund built to accelerate the development of new …See details»